KIT and gastrointestinal stromal tumor: We hypothesized that treatment with HHT reduces KIT protein levels, thereby decreasing KIT activation as well as its downstream signaling cascades ultimately leading to GIST cell apoptosis in an imatinib-sensitive as well as imatinib-resistant setting.